Nohla Therapeutics
Seattle
About Nohla Therapeutics
Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $120.5M
- Funding stage: Early Stage Venture
- Last round: Series B (Jul 2018)
- Website: nohlatherapeutics.com
- Phone: +1(206)519-5300
Industries & Categories
Biotechnology, Health Diagnostics, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/nohla-therapeutics-34550 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.